OCWP
STOK icon

Owl Creek Wealth Partners’s Stoke Therapeutics STOK Stock Holding History

Owl Creek Wealth Partners’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.91K Hold
150
– – ﹤0.01% 1019
2026
Q1 		$4.88K Buy
+150
New +$4.92K ﹤0.01% 976

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Owl Creek Wealth Partners's STOK Position: Q2 2026 in Review

Owl Creek Wealth Partners held its Stoke Therapeutics (STOK) position steady in Q2 2026 at 150 shares worth $4.91K. The position accounts for ﹤0.01% of the portfolio, ranked #1019.

Owl Creek Wealth Partners first reported a position in STOK in Q1 2026 and has held it in 2 quarters since. 179 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Owl Creek Wealth Partners held 150 shares of Stoke Therapeutics worth $4.91K as of Q2 2026.
  • Owl Creek Wealth Partners left its Stoke Therapeutics share count unchanged in Q2 2026.
  • Stoke Therapeutics made up ﹤0.01% of Owl Creek Wealth Partners's portfolio in Q2 2026, its #1019 holding.
  • Owl Creek Wealth Partners first reported a position in Stoke Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 179 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Owl Creek Wealth Partners's 13F filing for Q2 2026, filed 20 Jul 2026.